Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,050 | 1,090 | 25.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects | 80 | ACCESS Newswire | MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for... ► Artikel lesen | |
Di | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
18.06. | MIRA Pharmaceuticals' ketamine analog accepted for publication | 3 | Investing.com | ||
18.06. | MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology | 338 | ACCESS Newswire | MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic... ► Artikel lesen | |
MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
17.06. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
28.05. | MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program | 230 | ACCESS Newswire | The company will engage in BIO One-on-One Partnering meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. MIAMI, FL... ► Artikel lesen | |
28.05. | MIRA Pharmaceuticals gibt klinische Fortschritte und Akquisitionsupdate bekannt | 4 | Investing.com Deutsch | ||
21.05. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
14.05. | MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | 8 | SEC Filings | ||
08.05. | MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M | 8 | Seeking Alpha | ||
08.05. | MIRA Pharmaceuticals erwirbt SKNY in strategischem Schritt | 4 | Investing.com Deutsch | ||
08.05. | MIRA Pharmaceuticals to acquire SKNY in strategic move | 3 | Investing.com | ||
08.05. | MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review | 507 | ACCESS Newswire | With valuations confirmed by the board, MIRA advances strategic acquisition targeting obesity and nicotine dependence, which includes a $5 million contribution in cash or assets from SKNY to be transferred... ► Artikel lesen | |
08.05. | EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million | 5 | Benzinga.com | ||
06.05. | MIRA Pharmaceuticals berichtet über sicheres Profil für Ketamir-2 | 9 | Investing.com Deutsch | ||
06.05. | MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity | 130 | ACCESS Newswire | Preclinical data supports the advancement of oral Ketamir-2 as a safe, next-generation alternative to ketamine, with ongoing momentum in Phase I clinical trial enrollment MIAMI, FL / ACCESS Newswire... ► Artikel lesen | |
06.05. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
06.05. | EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study | 4 | Benzinga.com | ||
23.04. | MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 | 1 | Seeking Alpha | ||
23.04. | MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation | 161 | ACCESS Newswire | MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 89,70 | -0,88 % | Biotech Report: Biontech rutschen ab; Sektor an der Wall Street leichter | (shareribs.com) Frankfurt / New York 23.06.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend leichter. Unter anderem sacken Biontech kräftig ab. Auch an der Wall Street bewegt sich der... ► Artikel lesen | |
EVOTEC | 7,160 | +4,04 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BB BIOTECH | 32,100 | -0,62 % | EQS-PVR: BB BIOTECH AG: Disclosure of Shareholdings | EQS Voting Rights Announcement: BB BIOTECH AG
Disclosure of Shareholdings
23.06.2025 / 07:00 CET/CEST
Dissemination of a Voting Rights Announcement... ► Artikel lesen | |
QIAGEN | 40,130 | -0,59 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
CUREVAC | 4,650 | +0,52 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
AMGEN | 238,40 | -0,21 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
NOVAVAX | 5,536 | -1,02 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
STRYKER | 337,60 | +1,38 % | Kurs der Stryker-Aktie verharrt auf Vortags-Niveau (324,7763 €) | Am US-amerikanischen Aktienmarkt ist die Stryker-Aktie aktuell unauffällig. Der jüngste Kurs betrug 374,99 US-Dollar. Die Wertschätzung der Börsenteilnehmer für die Aktie von Stryker hat sich heute... ► Artikel lesen | |
BIOGEN | 109,10 | +0,28 % | Biogen Inc.: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results | Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children... ► Artikel lesen | |
ILLUMINA | 80,82 | +2,52 % | Standard BioTools Inc.: Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina | Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single... ► Artikel lesen | |
CRISPR THERAPEUTICS | 41,200 | +1,98 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
AAP IMPLANTATE | 1,520 | +4,83 % | EQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: aap Implantate AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
aap Implantate AG: Vorabbekanntmachung... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,800 | +1,69 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
OCUGEN | 0,897 | +0,67 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,483 | +7,55 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen |